Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$0.37 - $1.04 $75 - $212
-204 Reduced 1.37%
14,642 $5,000
Q2 2023

Aug 14, 2023

BUY
$0.74 - $1.1 $10,986 - $16,330
14,846 New
14,846 $14,000
Q2 2022

Aug 08, 2022

SELL
$1.28 - $2.31 $13,167 - $23,762
-10,287 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.82 - $3.5 $349 - $672
-192 Reduced 1.83%
10,287 $23,000
Q4 2021

Feb 14, 2022

SELL
$1.21 - $2.7 $594 - $1,325
-491 Reduced 4.48%
10,479 $14,000
Q3 2021

Nov 12, 2021

SELL
$2.59 - $3.36 $170 - $221
-66 Reduced 0.6%
10,970 $29,000
Q2 2021

Aug 12, 2021

SELL
$3.11 - $4.87 $71 - $112
-23 Reduced 0.21%
11,036 $37,000
Q1 2021

May 14, 2021

BUY
$3.66 - $7.67 $40,475 - $84,822
11,059 New
11,059 $48,000

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $112M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Eqis Capital Management, Inc. Portfolio

Follow Eqis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.